Evaluate the Efficacy and Safety of NYX-2925 in Subjects With Fibromyalgia
Condition: Fibromyalgia
MeSH terms: Fibromyalgia; Myofascial Pain Syndromes
Intervention: NYX-2925; Placebo oral capsule
Intervention description: NYX-2925 is a novel small molecule that modulates the N-methyl-D-aspartate receptor (NMDAR).; Matching placebo capsules.
Phase: Phase 2
Study type: Interventional
Primary purpose: Treatment
Intervention model: Single Group Assignment
Intervention model description: All subjects will receive placebo, NYX-2925 20 mg QD, NYX-2925 200 mg QD for sequential 2 week treatment periods, then go into Follow-up for 1 week.
Masking: None (Open Label)
Masking description: Subjects are masked to the sequence in which they are taking placebo QD, NYX-2925 20 mg QD, NYX-2925 200 mg QD.
Enrollment: 22.0
Sex: Female
Minimum age: 18 Years
Maximum age: 70 Years
Healthy volunteers: No
Keywords: Fibromyalgia

Summary:

      The primary objective is to determine whether daily dosing with NYX-2925 changes markers of
      central pain processing in subjects with fibromyalgia by evaluating changes in evoked pain,
      and visual stimulation, functional magnetic resonance imaging (fMRI), resting state function
      connectivity magnetic resonance imaging (rs-fcMRI) and proton magnetic resonance spectroscopy
      (H-MRS) in fibromyalgia subjects on active drug versus placebo.
    

Eligibility criteria:

        Inclusion Criteria:

          1. Subjects meets the 2010 American College of Rheumatology (ACR) criteria for
             fibromyalgia.

          2. Self-reported clinical pain ≥ 4 and on the Numeric Pain Rating Scale (NPRS) at
             screening and baseline.

          3. Subject receives and agrees to remain on their stable fibromyalgia treatment plan
             established at least 14 days prior to dosing.

          4. Subject agrees to use only non-steroidal anti-inflammatory (NSAID) or acetaminophen
             treatment as needed for breakthrough pain, and/or, zopiclone, zolpidem, zaleplon, or
             eszopiclone for sleep (if needed).

          5. Right handed.

          6. Calculates creatinine clearance ≥ 60 mL/minute.

          7. Female subjects of child bearing potential with a negative serum pregnancy test prior
             to entry into the study and who are practicing an adequate method of birth control
             (e.g., surgical sterilization, oral or parenteral contraceptives, intrauterine device
             that is considered safe for MRI procedures, barrier [condom with spermicide]) and who
             do not plan to become pregnant, breastfeed, or donate ova during the course of the
             study and for 28 days after the final administration of investigational product.

          8. Ability to understand the requirements of the study, provide written informed consent,
             abide by the study restrictions, and agree to return for the required assessments.

        Exclusion Criteria:

          1. Current or expected use of opioid or narcotic analgesics, monoamine oxidase inhibitors
             (MAOIs), tricyclic antidepressants, gabapentins, topiramate, anticonvulsants,
             benzodiazepines, and sedatives, or hypnotics.

          2. Unstable doses of allowed antidepressants or muscle relaxants. Use of NSAIDs or
             acetaminophen 24 hours prior to imaging procedures is prohibited.

          3. Pain due to concurrent disease such as rheumatoid arthritis, systemic lupus
             erythematosus, inflammatory bowel disease, or other chronic widespread pain
             condition(s) that may confound fibromyalgia pain.

          4. Untreated endocrine disorder that may confound fibromyalgia assessments.

          5. Psychiatric or cognitive disorder (e.g., current schizophrenia, severe depression,
             suicidal ideation, dementia, etc.).

          6. Clinically significant alcohol or other substance abuse within the last 2 years.

          7. Positive screen for medically inappropriate or illegal use of drugs of abuse.

          8. Current treatment with medications such as ketamine, amantadine, dextromethorphan,
             memantine, methadone, dextropropoxyphene, or ketobemidone.

          9. History of allergy, sensitivity, or intolerance to medications such as ketamine,
             amantadine, dextromethorphan, memantine, methadone, dextropropoxyphene, or
             ketobemidone.

         10. Women, who are pregnant, breast feeding, or planning to become pregnant or donate ova
             during the course of the study and for 28 days after the final administration of
             investigational product.

         11. Huntington's, Parkinson's, Alzheimer's, Multiple Sclerosis, or history of seizures,
             epilepsy, or strokes.

         12. Contraindications to fMRI procedures. These may include but are not limited to:
             surgical clips, surgical staples, metal implants, and certain metallic dental
             material.

         13. Current or habitual use (within the last 12 months) of artificial nails, nails
             enhancements, or nail extensions that cover any portion of either thumbnail.

         14. Abnormal laboratory results, medical history, or concurrent conditions that would
             preclude safe study participation, or interfere with study procedures/assessments.

         15. Impaired liver function.

         16. Known history of significant heart condition or high blood pressure.

         17. Current evidence of dysplasia or history of cancer malignancy (including lymphoma and
             leukemia) in the last 5 years.

         18. Human immunodeficiency virus (HIV) infection, hepatitis, or other ongoing infectious
             disease.

         19. History of severe kidney or liver impairment.

         20. History of migraine.

         21. History of lower limb vascular surgery or current lower limb vascular dysfunction.

         22. Received an investigational drug or device within 30 days of dosing.

         23. Previous treatment with NYX-2925.

         24. Resting heart rate < 45 or ≥ 95 beats per minute.